Get the Stockscreener App
1.18
1.72%
0.02
After Hours:
1.17
-0.01
-0.85%
Femasys Inc stock is traded at $1.18, with a volume of 145.10K.
It is up +1.72% in the last 24 hours and down -0.84% over the past month.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
See More
Previous Close:
$1.16
Open:
$1.14
24h Volume:
145.10K
Relative Volume:
0.35
Market Cap:
$31.49M
Revenue:
$950.10K
Net Income/Loss:
$-16.69M
P/E Ratio:
-1.4217
EPS:
-0.83
Net Cash Flow:
$-15.16M
1W Performance:
+1.72%
1M Performance:
-0.84%
6M Performance:
-1.67%
1Y Performance:
-8.53%
1-Day Range:
$1.14
$1.21
1-Week Range:
$1.12
$1.21
52-Week Range:
$0.86
$1.80
Femasys Inc Stock (FEMY) Company Profile
Name
Femasys Inc
Sector
Industry
Phone
770-500-3910
Address
3950 JOHNS CREEK COURT, SUWANEE
Compare FEMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
1.18 | 31.49M | 950.10K | -16.69M | -15.16M | -0.83 |
|
ISRG
Intuitive Surgical Inc
|
531.82 | 184.23B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
167.00 | 58.65B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
97.38 | 47.15B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
240.66 | 35.34B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
81.57 | 16.25B | 3.90B | 392.30M | 288.10M | 1.95 |
Femasys Inc Stock (FEMY) Latest News
Geode Capital Management LLC Acquires 9,681 Shares of Femasys Inc. (NASDAQ:FEMY) - Defense World
Femasys Inc. (NASDAQ:FEMY) Sees Significant Drop in Short Interest - Defense World
Femasys (NASDAQ:FEMY) Stock Price Down 3.2% – Time to Sell? - Defense World
FEMY’s 52-Week Rollercoaster: From $0.86 to $1.80 – What’s Next for Investors? - investchronicle.com
FemBloc Delivery System Approved by European Regulators - Medical Product Outsourcing
Femasys Reports Wider-Than-Expected Annual Loss, But Retail Continues To Be Optimistic - Asianet Newsable
HC Wainwright Reaffirms “Buy” Rating for Femasys (NASDAQ:FEMY) - Defense World
Femasys Positioned for Growth with Innovative Products and Strategic Partnerships - TipRanks
H.C. Wainwright maintains Femasys stock Buy rating, $15 target By Investing.com - Investing.com India
H.C. Wainwright maintains Femasys stock Buy rating, $15 target - Investing.com
Femasys Positioned for Growth in 2025 with Strategic Partnerships and Regulatory Progress - TipRanks
Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates - MSN
Femasys earnings missed by $0.04, revenue fell short of estimates - Investing.com Canada
Femasys reports FY24 EPS (85c), consensus (81c) - TipRanks
Femasys Inc. FY EPS USD -0.85 - Marketscreener.com
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update - GlobeNewswire
FEMASYS Earnings Preview: Recent $FEMY Insider Trading, Hedge Fund Activity, and More - Nasdaq
FY2026 Earnings Forecast for Femasys Issued By HC Wainwright - Defense World
HC Wainwright Raises Femasys (NASDAQ:FEMY) Price Target to $15.00 - The AM Reporter
HC Wainwright Boosts Femasys (NASDAQ:FEMY) Price Target to $15.00 - Defense World
H.C. Wainwright raises Femasys stock price target to $15 By Investing.com - Investing.com Australia
Femasys price target raised to $15 from $12 at H.C. Wainwright - Yahoo Finance
H.C. Wainwright raises Femasys stock price target to $15 - Investing.com
Femasys (FEMY) to Release Earnings on Thursday - Defense World
Femasys Gains Momentum with EU Approval and Strategic Partnerships, Boosting Buy Rating - TipRanks
Femasys Announces Partnership with CNY Fertility, National - GlobeNewswire
Femasys Secures Game-Changing Partnership: FemaSeed Now Available at 11 Leading Fertility Centers - StockTitan
Femasys’s Strategic Expansion and Promising Clinical Results Justify Buy Rating - TipRanks
Assessing Femasys: Insights From 4 Financial Analysts - Benzinga
Femasys Signs FemBloc Commercial Distribution Deals -March 18, 2025 at 09:58 am EDT - Marketscreener.com
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain - GlobeNewswire
Femasys Breaks Into European Market: First Global Deal for Revolutionary Birth Control Solution - StockTitan
HC Wainwright Reiterates “Buy” Rating for Femasys (NASDAQ:FEMY) - Defense World
H.C. Wainwright maintains Femasys stock Buy rating, $12 target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Femasys stock Buy rating, $12 target - Investing.com
Femasys gains CE mark for non-surgical birth control system By Investing.com - Investing.com Australia
Femasys Achieves CE Mark for FemBloc, Paving the Way for European Market Entry and Justifying Buy Rating - TipRanks
Femasys Receives CE Mark for FemBloc Non-Surgical Permanent Birth Control System - Femtech Insider
Femasys Inc Stock (FEMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):